Medical Supply Chain Resiliency Act

S 2115, the Medical Supply Chain Resiliency Act, establishes a framework for the U.S. to negotiate agreements with "trusted trade partners" to strengthen medical supply chains. It requires the President to partner only with countries meeting specific criteria, such as maintaining open trade during health emergencies, protecting intellectual property, and reducing trade barriers for medical goods like drugs and devices. The bill mandates congressional oversight, including 30-day review periods for agreements and regular reports on negotiations. These agreements aim to diversify suppliers, ensure reliable access to critical medical products during crises, and streamline cross-border movement of medical goods. The law directly affects U.S. healthcare supply security and international trade relationships with designated medical goods suppliers.